KMS Medisurgi Independent Director Mr. Pratik Pravin Tarpara Steps Down After Completion of First Term

1 min read     Updated on 08 May 2026, 02:56 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

KMS Medisurgi Limited has disclosed the cessation of Mr. Pratik Pravin Tarpara (DIN-08689556) as Independent Director, effective 30th September 2025, upon completion of his first term of appointment. The filing was made under Regulation 30 of the SEBI Listing Regulations. Mr. Tarpara held no directorships in other listed companies, and there are no board committee updates arising from the change. The Board acknowledged his contributions and guidance during his tenure.

powered bylight_fuzz_icon
39777990

*this image is generated using AI for illustrative purposes only.

KMS Medisurgi Limited has informed stock exchanges of the cessation of Mr. Pratik Pravin Tarpara (DIN-08689556) as an Independent Director of the company, effective 30th September 2025. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Tarpara's departure follows the completion of his first term of appointment as an Independent Director.

Director Cessation Details

The company filed the disclosure in compliance with Clause 7 of Para A of Part A of Schedule III of the SEBI Listing Regulations, read with the SEBI Circular dated 13 July 2023, and the SEBI master circular dated November 11, 2024. The key details pertaining to the cessation are outlined below:

Parameter: Details
Name of Director: Mr. Pratik Pravin Tarpara
DIN: 08689556
Reason for Cessation: Completion of first term of appointment as Independent Director
Date of Cessation: 30th September 2025
Directorship in Other Listed Companies: Nil
Board Committee Update: Nil
Relationship Between Directors: Not Applicable

Board Acknowledgement

The Board of Directors and Management of KMS Medisurgi placed on record their deep appreciation for the invaluable contributions, guidance, and services rendered by Mr. Pratik Pravin Tarpara during his tenure as an Independent Director. The disclosure was signed by Siddharth Kanakia, Managing Director (DIN: 07595098), on behalf of the company from Mumbai.

Historical Stock Returns for KMS Medisurgi

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%+272.06%

Who will KMS Medisurgi appoint as a replacement Independent Director, and how might the new appointment affect the board's composition and governance structure?

How will the departure of Mr. Tarpara impact the quorum and functioning of key board committees such as the Audit or Nomination & Remuneration Committee at KMS Medisurgi?

Given the regulatory requirement for a minimum number of Independent Directors under SEBI norms, what is the timeline within which KMS Medisurgi must fill this vacancy to remain compliant?

KMS Medisurgi Limited Submits SEBI Compliance Certificate for Q4FY26

1 min read     Updated on 15 Apr 2026, 10:39 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

KMS Medisurgi Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) with BSE Limited on 14.04.2026. The certificate, prepared by registrar KFIN Technologies Limited, confirms that all company shares remain in dematerialised form with no re-materialisation requests received during the quarter ended 31st March, 2026, demonstrating continued regulatory compliance.

powered bylight_fuzz_icon
37818595

*this image is generated using AI for illustrative purposes only.

KMS Medisurgi Limited has submitted its quarterly compliance certificate under SEBI regulations for the quarter ended 31st March, 2026. The Mumbai-based company filed the mandatory certificate with BSE Limited on 14.04.2026, fulfilling its regulatory obligations under the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Details

The certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation requires companies to provide quarterly confirmations regarding the status of their share dematerialisation and any re-materialisation requests received during the reporting period.

Parameter: Details
Reporting Quarter: Q4FY26 (ended 31st March, 2026)
Filing Date: 14.04.2026
Regulation: SEBI Regulation 74(5)
Scrip Code: 540468
Filing Authority: BSE Limited

Certificate Confirmation

KFIN Technologies Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate on 3.04.2026. The certificate confirms that Regulation 74(5) is not applicable to KMS Medisurgi Limited during the quarter ended 31st March, 2026.

The key findings of the certificate include:

  • All company shares remain in dematerialised (demat) form
  • No requests for re-materialisation were received from shareholders during Q4FY26
  • Complete compliance with SEBI depositories regulations maintained

Company and Agent Details

The certificate was signed by Siddharth Kanakia, Managing Director of KMS Medisurgi Limited (DIN: 07595098), and submitted from the company's Mumbai office located at Plot No-297/301 May Building, Marine Lines (East). KFIN Technologies Limited, with its registered office in Hyderabad's Financial District, provided the registrar services and certificate confirmation through Vice President Dnyanesh Gharote.

Regulatory Significance

This quarterly filing demonstrates KMS Medisurgi's continued adherence to SEBI's transparency and compliance requirements. The confirmation that all shares remain in demat form reflects the company's alignment with modern securities market practices and investor preferences for electronic shareholding.

Historical Stock Returns for KMS Medisurgi

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%0.0%0.0%+272.06%

What strategic initiatives might KMS Medisurgi pursue in FY27 following their consistent regulatory compliance track record?

How could the company's 100% dematerialized shareholding structure facilitate potential future fundraising or M&A activities?

Will KMS Medisurgi consider expanding their registrar services beyond KFIN Technologies as they scale operations?

More News on KMS Medisurgi

1 Year Returns:0.00%